Tumor defense by murine cytotoxic T cells specific for peptide bound to nonclassical MHC class I

Cancer Research

Volumn 58, Issue 20, 1998, Pages 4682-4687

  Griffiths, Emily ^a   Ong, Helena ^b   Soloski, Mark J ^b   Bachmann, Martin F ^a   Ohashi, Pamela S ^a   Speiser, Daniel E ^c,d  

^a UNIVERSITY OF TORONTO   (Canada)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF LAUSANNE   (Switzerland)

^d LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN RECOGNITION; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; LYMPHOCYTOTOXICITY; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR IMMUNITY; TUMOR IMMUNOLOGY;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CROSS REACTIONS; HISTOCOMPATIBILITY ANTIGENS CLASS I; KILLER CELLS, NATURAL; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0032532088     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Zinkernagel, R. M., and Doherty, P. C. MHC-restricted cytotoxic T cells: studies on the biological role of polymorphic major transplantation antigens determining T cell restriction specificity, function and responsiveness. Adv. Immunol., 27: 52-142, 1979.
2. Bevan, M. J. The major histocompatibility complex determines susceptibility to cytotoxic T cells directed against minor histocompatibility antigens. J. Exp. Med., 142: 1349-1364, 1975.
3. Bailey, D. Genetics of histocompatibility in mice. I. New loci and congenic lines. Immunogenetics, 2: 249-256, 1975.
4. Simpson, E., and Gordon, R. D. Responsiveness to HY antigen, Ir gene complementation and target cell specificity. Immunol. Rev., 35: 59-75, 1977.
5. Rammensee, H-G., Robinson, P. J., Crisanti, A., and Bevan, M. J. Restricted recognition of β2-microglobulin by cytotoxic T lymphocytes. Nature (Lond.), 319: 502-504, 1986.
6. Goulmy, E., Termijtelen, A., Bradley, B. A., and Van Rood, J. J. Y-antigen killing by T cells of woman is restricted by HLA. Nature (Lond.), 266: 544-545, 1977.
7. Speiser, D. E., Zürcher, T., Ramseier, H., Hengartner, H., Staeheli, P., Haller, O., and Zinkernagel, R. M. Nuclear myxovirus-resistance protein Mx is a minor histocompatibility antigen. Proc. Natl. Acad. Sci. USA, 87: 2021-2025, 1990.
8. Beatty, P. G. Minor histocompatibility antigens. Exp. Hematol., 21: 1514-1516, 1993.
9. Boon, T., Cerottini, J-C., Van den Eynde, B., van der Bruggen, P., and Van Pel, A. Tumor antigens recognized by T lymphocytes. Annu. Rev. Immunol., 12: 337-365, 1994.
10. Slingluff, C. L., Jr., Hunt, D. F., and Engelhard, V. H. Direct analysis of tumor-associated peptide antigens. Curr. Opin. Immunol., 6: 733-740, 1994.
11. Melief, C. J. M., and Kast, W. M. T-cell immunotherapy of tumors by adoptive transfer of cytotoxic T lymphocytes and by vaccination with minimal essential epitopes. Immunol. Rev., 145: 167-177, 1994.
12. Houghton, A. N. Cancer antigens: immune recognition of self and altered self. J. Exp. Med., 180: 1-4, 1994.
13. Kawakami, Y., Eliyahu, S.., Delgado, C. H., Robbins, P. F., Sakaguchi, K., Appella, E., Yannelli, J. R., Adema, G. J., Miki, T., and Rosenberg, S. A. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc. Natl. Acad. Sci. USA, 91: 6458-6462, 1994.
14. Peoples, G. E., Goedegebuure, P. S., Smith, R., Linehan, D. C., Yoshino, I., and Eberlein, T. J. Breast and ovarian cancer-specific T lymphocytes recognize the same HER2/neu-derived peptide. Proc. Natl. Acad. Sci. USA, 92: 432-436, 1995.
15. Theobald, M., Biggs, J., Dittmer, D., Levine, A. J., and Sherman, L. A. Targeting p53 as a general tumor antigen. Proc. Natl. Acad. Sci. USA, 92: 11993-11997, 1995.
16. Mandelboim, O., Berke, G., Fridkin, M., Feldman, M., Eisenstein, M., and Eisenbach, L. CTL induction by a tumour-associated antigen octapeptide derived from a murine lung carcinoma. Nature (Lond.), 369: 67-71, 1994.
17. Noguchi, Y., Chen, Y. T., and Old, L. J. A mouse mutant p53 product recognized by CD4+ and CD8+ T cells. Proc. Natl. Acad. Sci. USA, 91: 3171-3175, 1994.
18. Stroynowski, I., and Lindahl, K. F. Antigen presentation by non-classical class I molecules. Curr. Opin. Immunol., 6: 38-44, 1994.
19. Kurlander, R. J., Shawar, S. M., Brown, M. L., and Rich, R. R. Specialized role of a murine class I-b MHC molecule in prokaryotic host defense. Science (Washington DC), 257: 678-679, 1992.
20. Loveland, B. E., Wang, C. R., Yonekawa, H., Hermel, E., and Fischer-Lindahl, K. Maternally transmitted histoeompatibility antigen of mice: a hydrophobic peptide of a mitochondrially encoded protein. Cell, 60: 971-980, 1990.
21. Kawano, T., Cui, J., Koezuka, Y., Toura, I., Kaneko, Y., Motoki, K., Ueno, H., Nakagawa, R., Sato, H., Kondo, E., Koseki, H., and Tanaguchi, M. CD1d-restricted and TCR-mediated activation of Vα14 NKT cells by glycosylceramides. Science (Washington DC), 278: 1626-1629, 1997.
22. Stroynowski, I. Molecules related to class-I major histocompalibility complex antigens. Annu. Rev. Immunol., 8: 501-530, 1990.
23. Soloski, M. J., DeCloux, A., Aldrich, C. J., and Forman, J. Structural and functional characteristics of the class 1B molecule. Qa-1. Immunol. Rev., 147: 67-89, 1995.
24. Stroynowski, I. Tissue-specific, peptide-binding transplantation antigens: lessons from the Qa-2 system. Immunol. Rev., 147: 91-108, 1995.
25. b. J. Immunol., 158: 2183-2191, 1997.
26. Levitsky, H. I., Lazenby, A., Hayashi, R. J., and Pardoll, D. M. In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression. J. Exp. Med., 179: 1215-1224, 1994.
27. Imani, F., and Soloski, M. J. Heat shock proteins can regulate expression of the Tla region-encoded class Ib molecule Qa-1. Proc. Natl. Acad. Sci. USA, 88: 10475-10479, 1991.
28. Aldrich, C. J., DeCloux, A., Woods, A. S., Cotter, R. J., Soloski, M. J., and Forman, J. Identification of a tap-dependent leader peptide recognized by alloreactive T cells specific for a class 1b antigen. Cell, 79: 649-658, 1994.
29. Cobbold, S. P., Jayasuriya, A., Nash, A., Prospero, T. D., and Waldmann, H. Therapy with monoclonal antibodies by elimination of T cell subsets in vivo. Nature (Lond.), 312: 548-551, 1984.
30. Geraghty, D. E., Stockschleader, M., Ishitani, A., and Hansen, J. A. Polymorphism at the HLA-E locus predates most HLA-A and -B polymorphism. Hum. Immunol., 33: 174-184, 1992.
31. Gomez-Casado, E., Martinez-Laso, J., Vargas-Alarcon, G., Varela, P., Diaz-Campos, N., Alvarez, M., Alegre, R., and Arnaiz-Villena, A. Description of a new HLA-E (E*01031) allele and its frequency in the Spanish population. Hum. Immunol., 54: 69-73, 1997.
32. Geraghty, D. E., Wei, X. H., Orr, H. T., and Koller, B. H. Human leukocyte antigen F (HLA-F): an expressed HLA gene composed of a class I coding sequence linked to a novel transcribed repetitive element. J. Exp. Med., 171: 1-18, 1990.
33. Uchigiri, C., Mizuno, S., Wada, K., Tsutsumi, M., Kato, T., Kamiya, T., and Ozawa, K. An identification of the HLA-F null allele in Japanese. Immunogenetics, 45: 466-467, 1997.
34. Rotzschke, O., Falk, K., Stevanovic, S., Grahovac, B., Soloski, M. J., Jung, G., and Rammensee, H-G. Qa-2 molecules are peptide receptors of higher stringency than ordinary class I molecules. Nature (Lond.), 361: 642-644, 1993.
35. Joyce, S., Tabaczewski, P., Angeletti, R. H., Nathenson, S. G., and Stroynowski, I. A nonpolymorphic major histocompatibility complex class Ib molecule binds a large array of diverse self-peptides. J. Exp. Med., 179: 579-588, 1994.
36. Lopez-Botet, M., Moretta, L., and Strominger, J. L. NK-cell receptors and recognition of MHC class I molecules. Immunol. Today, 17: 212-214, 1996.
37. Lanier, L. L., and Phillips, J. H. Inhibitory MHC class I receptors on NK cells and T cells. Immunol. Today, 17: 86-91, 1996.
38. Braud, V. M., Allan, D. S. J., O'Callaghan, C. A., Söderström, K., D'Andrea, A., Ogg, G. S., Lazetic, S., Young, N. T., Bell, J. I., Phillips, J. H., Lanier, L. L., and McMichael, A. J. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature (Lond.), 391: 795-799, 1998.
39. Borrego, F., Ulbrecht, M., Weiss, E. H., Coligan, J. E., and Brooks, A. G. Recognition of human histocompatibility leukocyte antigen (HLA)-E complexed with HLA class I signal sequence-derived peptides by CD94/NKG2 confers protection from natural killer cell-mediated lysis. J. Exp. Med., 187: 813-816, 1998.
40. Bachmann, M. F., Sebzda, E., Kündig, T. M., Shahinian, A., Speiser, D. E., Mak, T. W., and Ohashi, P. S. T cell responses are governed by avidity and costimulatory thresholds. Eur. J. Immunol., 26: 2017-2022, 1996.
41. Parkhurst, M. R., Salgaller, M. L., Southwood, S., Robbins, P. F., Sette, A., Rosenberg, S. A., and Kawakami, Y. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J. Immunol., 157: 2539-2548, 1996.
42. Valmori, D., Fonteneau, J-F., Lizana, C. M., Gervois, N., Liénhard, D., Rimoldi, D., Jongeneel, V., Jotereau, F., Cerottini, J-C., and Romero, P. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J. Immunol., 160: 1750-1758, 1998.
43. Zhai, Y., Yang, J. C., Spiess, P., Nishimura, M. I., Overwijk, W. W., Roberts, B., Restifo, N. P., and Rosenberg, S. A. Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART1 and gp100. J. Immunother., 20: 15-25, 1997.
44. Rosenberg, S. A., Yang, J. C., Schwartzentruber, D. J., Hwu, P., Marincola, F. M., Topalian, S. L., Restifo, N. P., Dudley, M. E., Schwarz, S. L., Spiess, P. J., Wunderlich, J. R., Parkhurst, M. R., Kawakami, Y., Seipp, C. A., Einhorn, J. H., and White, D. E. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med., 4: 321-327, 1998.